Medication info

Youngjin Daryu Long-acting Tablets 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Pink, biconvex, oval-shaped controlled-release film-coated tablet
Packaging
30 tablets/box[(6 tablets/PTP)*5], 30 tablets/bottle
Approval status
Active

MFDS item code 202301895 · Approved 2023.06.21

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from concomitant therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the current doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Use in elderly patients).

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This drug is used to help control blood sugar in adults with type 2 diabetes who are using dapagliflozin and metformin together. When taken in conjunction with diet and exercise therapies, it can effectively lower blood sugar levels. Particularly in patients whose blood sugar is not adequately controlled, those with or at risk for cardiovascular disease should consult with a healthcare professional regarding the impact of dapagliflozin on cardiovascular events and be monitored carefully. This drug is used to improve blood sugar control in type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous experience with antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from concomitant therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the current doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must not be crushed, cut, or chewed. Occasionally, inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Use in elderly patients).

Precautions

This drug is used for the treatment of diabetes and should not be used in patients with poor kidney function or certain health conditions. This medication can rarely cause a serious metabolic complication called lactic acidosis, so patients with decreased kidney function or liver dysfunction should be particularly cautious. Use with other diabetes medications, such as insulin or sulfonylureas, may result in hypoglycemic symptoms, so blood sugar levels should be closely monitored when used in combination. Before and after surgery or diagnostic tests that use radiocontrast agents, the use of this drug should be temporarily discontinued, and it should be resumed only after verifying normal kidney function. Women who are pregnant or breastfeeding should not take this medication, and if planning a pregnancy, should consult with a doctor. Elderly patients or those with reduced fluid volume or states of dehydration or severe infection should have their kidney function and blood pressure monitored regularly before and after taking this drug. Genital and urinary tract infections may occur during treatment, so if any related symptoms appear, healthcare professionals should be informed immediately. Vitamin B12 levels may decrease; therefore, it is advisable to monitor vitamin B12 concentrations during long-term use. Excessive alcohol consumption may exacerbate the side effects of this drug and should be avoided, and care is required when used with other medications that may affect blood sugar control. This drug may have a weight loss effect; however, symptoms such as hypoglycemia or dehydration may occur, so consulting a doctor immediately if symptoms arise is necessary. Dizziness or hypotension may occur during treatment, caution is advised when driving or operating machinery. This drug should be kept out of reach of children and stored in its original container to prevent misuse or deterioration in quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • pain during urination
  • polyuria
  • nocturia
  • vulvar itch
  • genital itch
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • lung malignancies
  • uterine fibroma
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcers
  • irritable bowel syndrome
  • salivary gland masses
  • dental pain
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural deafness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it should be stored in a sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink, biconvex, oval-shaped controlled-release film-coated tablet

Package unit

30 tablets/box[(6 tablets/PTP)*5], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.